Elisa Kits

Epitope and Paratope Mapping by HDX-MS Combined with SPR Elucidates the Difference in Bactericidal Activity of Two Anti-NadA Monoclonal Antibodies

Epitope and Paratope Mapping by HDX-MS Combined with SPR Elucidates the Difference in Bactericidal Activity of Two Anti-NadA Monoclonal Antibodies

Characterization of antigen-antibody interactions is essential for understanding antibody-mediated safety towards pathogens, biopharmaceutical growth, in addition to analysis of the immune response put up vaccination. Bexsero is a multicomponent vaccine towards Neisseria meningitidis serogroup B through which one of many key vaccine antigens is Neisserial adhesin A (NadA), a trimeric coiled-coil protein. Two NadA-specific monoclonal antibodies (mAbs) …

Epitope and Paratope Mapping by HDX-MS Combined with SPR Elucidates the Difference in Bactericidal Activity of Two Anti-NadA Monoclonal Antibodies Read More »

Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B

Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B

Staphylococcal enterotoxin B (SEB), one of many exotoxins produced by Staphylococcus aureus, is the important thing toxin that causes poisoning reactions and poisonous shock syndrome. Within the present analysis work, a novel human antibody named LXY8 was screened from a human phage show antibody library, and LXY8 blocked the interplay between SEB and the T …

Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B Read More »

Development of multi-epitope peptide-based vaccines against SARS-CoV-2

Development of multi-epitope peptide-based vaccines against SARS-CoV-2

Extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated a pandemic involving so excess of 32 million infections and 980,031 deaths. Efficient vaccines are urgently wanted to stop SARS-CoV-2 infections. No vaccines have but been accepted for licensure by regulatory businesses. Although host immune responses to SARS-CoV-2 infections are starting to be unravelled, efficient clearance …

Development of multi-epitope peptide-based vaccines against SARS-CoV-2 Read More »